MedTrace Logo

BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)

NCT00088530 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2020-02-05

Study results available
· View outcomes & findings →

Summary

BBR 2778 is a novel aza-anthracenedione that has activity in experimental tumors and shows reduced potential for cardiotoxicity in animal models. This cytotoxic agent has structural similarities with mitoxantrone as well as general similarities with anthracyclines (such as the tricyclic central quinoid chromophore).

Conditions

  • Lymphoma, Non-Hodgkin

Interventions

DRUG

pixantrone, cyclophosphamide, vincristine, rituximab, prednisone

Day 1: pixantrone (150 mg/m2), cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2), rituximab (375 mg/m2) Days 1-5: prednisone (100 mg/day)

DRUG

Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab

Day 1: cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2), rituximab (375 mg/m2) Days 1-5: prednisone (100 mg/day)

Sponsors & Collaborators

  • CTI BioPharma

    lead INDUSTRY

Principal Investigators

  • Simran Singh · Sr. Director, Clinical Operations

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2010-02-28
Completion
2010-07-31

Countries

  • United States
  • Argentina
  • Bulgaria
  • Costa Rica
  • Ecuador
  • Estonia
  • France
  • Germany
  • Hungary
  • India
  • Italy
  • Mexico
  • Panama
  • Peru
  • Poland
  • Romania
  • Russia
  • Ukraine
  • United Kingdom
  • Uruguay

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00088530 on ClinicalTrials.gov